Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.

Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Abstract Text:

Iclal Ocak,Marcelino Bernardo,Greg Metzger,Tristan Barrett,Peter Pinto,Paul S Albert,Peter L Choyke,Iclal Ocak,Marcelino Bernardo,Greg Metzger,Tristan Barrett,Peter Pinto,Paul S Albert,Peter L Choyke,

OBJECTIVE: The objectives of our study were to determine whether dynamic contrast-enhanced MRI performed at 3 T and analyzed using a pharmacokinetic model improves the diagnostic performance of MRI for the detection of prostate cancer compared with conventional T2-weighted imaging, and to determine which pharmacokinetic parameters are useful in diagnosing prostate cancer. SUBJECTS AND METHODS: This prospective study included 50 consecutive patients with biopsy-proven prostate cancer who underwent imaging of the prostate on a 3-T scanner with a combination of a sensitivity-encoding (SENSE) cardiac coil and an endorectal coil. Scans were obtained at least 5 weeks after biopsy. T2-weighted turbo spin-echo images were obtained in three planes, and dynamic contrast-enhanced images were acquired during a single-dose bolus injection of gadopentetate dimeglumine (0.1 mmol/kg). Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were estimated for T2-weighted and dynamic contrast-enhanced MRI. The following pharmacokinetic modeling parameters were determined and compared for cancer, inflammation, and healthy peripheral zone: K(trans) (forward volume transfer constant), k(ep) (reverse reflux rate constant between extracellular space and plasma), v(e) (the fractional volume of extracellular space per unit volume of tissue), and the area under the gadolinium concentration curve (AUGC) in the first 90 seconds after injection. RESULTS: Pathologically confirmed cancers in the peripheral zone of the prostate were characterized by their low signal intensity on T2-weighted scans and by their early enhancement, early washout, or both on dynamic contrast-enhanced MR images. The overall sensitivity, specificity, PPV, and NPV of T2-weighted imaging were 94%, 37%, 50%, and 89%, respectively. The sensitivity, specificity, PPV, and NPV of dynamic contrast-enhanced MRI were 73%, 88%, 75%, and 75%, respectively. K(trans), k(ep), and AUGC were significantly higher (p < 0.001) in cancer than in normal peripheral zone. The ve parameter was not significantly associated with prostate cancer. CONCLUSION: MRI of the prostate performed at 3 T using an endorectal coil produces high-quality T2-weighted images; however, specificity for prostate cancer is improved by also performing dynamic contrast-enhanced MRI and using pharmacokinetic parameters, particularly K(trans) and k(ep), for analysis. These results are comparable to published results at 1.5 T.

Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Publishing Authors By Initials

I Ocak,M Bernardo,G Metzger,T Barrett,P Pinto,PS Albert,PL Choyke,I Ocak,M Bernardo,G Metzger,T Barrett,P Pinto,PS Albert,PL Choyke,

For similar investigative techniques: epidemiologic methods: statistics as topic: sensitivity and specificity research abstracts see: investigative techniques: epidemiologic methods: statistics as topic: sensitivity and specificity research

PUBMED ID PMID:

MEDLINE DATE:

Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Intr

Journal: AJR. American journal of roentgenology

VOLUME: 189

Page Numbers: 849

Journal Abbreviation:

ISSN: 1546-3141

DAY: 3

MONTH: Oct

YEAR: 2007

Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7708173

Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Keywords Mesh Terms:

KEYWORDS: Sensitivity and Specificity

MESH TERMS: metabolism

Chemical & Substance for Abstract: Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Information

Substance Name: Gadolinium DTPA

Registry Number: 80529-93-7

Grant and Affiliation Information for Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.

AFFILIATION: Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

Country: United States

AGENCY: United States NCI

GRANT: N01-CO-12400

ACRONYM: CO

MEDLINETA: AJR Am J Roentgenol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters Related Publications

• CT and MRI of hepatic abscess in patients with chronic granulomatous disease.
• Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
• Is it possible to quantify fluorescence during optical endoscopy?
• Radiologic evaluation of hematuria: guidelines from the American College of Radiology's appropriateness criteria.
• The biologic basis of in vivo angiogenesis imaging.
• The clinical and imaging spectrum of pancreaticoduodenal lymph node enlargement.
• Tumor-targeted optical imaging in the management of peritoneal carcinomatosis.